TheraRadar

Pharma Intelligence, Simplified

Data updated: Mar 10, 2026

LIDODERM

LIDOCAINE
Dermatology Approved 1999-03-19
1
Indication
--
Phase 3 Trials
26
Years on Market

Details

Status
Prescription
First Approved
1999-03-19
Routes
TOPICAL
Dosage Forms
PATCH

Companies

Active Ingredient: LIDOCAINE

LIDODERM Approval History

Loading approval history...

What LIDODERM Treats

1 indications

LIDODERM is approved for 1 conditions since its original approval in 1999. These indications span multiple therapeutic areas including oncology, immunology, and more.

  • Post-Herpetic Neuralgia
Source: FDA Label

Drugs Similar to LIDODERM

FDA-approved drugs for similar conditions. Compare mechanisms and indications to understand treatment alternatives.

๐Ÿ”ฌ

Active Pipeline

Pro

Ongoing clinical trials by development phase

Loading...
โญ

Key Completed Trials

Pro

Completed studies with published results, ranked by significance

Loading...
๐Ÿ“Š

Trial Timeline

Full development history with FDA approval milestones

Loading...
Understanding FDA Approval Types
Count Type What it means
- ORIG Original approval - drug first enters market
- SUPPL - Efficacy New indication (new disease/condition approved)
- SUPPL - Labeling Label text changes (warnings, dosing updates)
- SUPPL - Manufacturing Production changes (new facility)
- SUPPL - Chemistry Formulation changes (new dosage strength)

Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.

LIDODERM FDA Label Details

Pro

Indications & Usage

FDA Label (PDF)

LIDODERM is indicated for relief of pain associated with post-herpetic neuralgia. It should be applied only to intact skin .

Want competitive intelligence?

See who's developing similar drugs and track their progress

View Pipeline Dashboard

Data Sources

Data sourced from official FDA and NIH databases. Click links to verify on original sources.